The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDe La Rue Regulatory News (DLAR)

Share Price Information for De La Rue (DLAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 97.00
Bid: 95.40
Ask: 97.00
Change: 3.00 (3.19%)
Spread: 1.60 (1.677%)
Open: 97.00
High: 97.20
Low: 95.20
Prev. Close: 94.00
DLAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

1 Sep 2022 12:10

RNS Number : 9739X
De La Rue PLC
01 September 2022
 

De La Rue plc

 

Director/PDMR Shareholding

Notification of transactions by persons discharging managerial responsibilities and persons closely associated with them

1 September 2022

De La Rue plc (the "Company") announces that on 31 August 2022 it granted awards under the De La Rue Performance Share Plan 2020 (the "PSP") to Clive Vacher, Rob Harding and Ruth Euling, each of whom is an Executive Director and a Person Discharging Managerial Responsibilities ("PDMR") of the Company. The granting of the awards creates a change in the interests of each of them in the ordinary shares of 44152/175p of the Company ("Shares"). The awards, which are structured as a nil-cost option (each an "Option"), were granted under the rules of the PSP as follows:

Name of Director/PDMR

Role

Number of Shares subject to the Option

Clive Vacher

CEO

454,059

Rob Harding

CFO

277,480

Ruth Euling

MD, Currency

252,158

 

The Options were granted on 31 August 2022 (the "Award Date"). The number of Shares contained in each Option was calculated by reference to a price of 84.55 pence, being the average of the closing middle market quotations for the Company's Shares for the five consecutive dealing days including and ending on 30 August 2022. The grant of the Options was deferred from its customary date due to the existence of inside information (which was announced to the market on 26 July 2022) and thereafter to allow the share price (used to determine the strike price as outlined above) to stabilise following that announcement.

Ordinarily, a grant would have been made with a face value equal of 100% of salary, in line with our directors' remuneration policy. As noted in the Directors' Remuneration Report within our 2022 Annual Report, to take into account recent shareholder experience of a fall in the share price and to avoid the potential for windfall gains if the share price recovers over the vesting period, the Remuneration Committee has reduced the number of Shares subject to the Option by 20% from the policy award that would otherwise have been made.

Each Option was granted such that vesting is subject to two equally-weighted performance conditions, which will be assessed independently, as outlined below:

Performance metric

Proportion

Below Threshold

Threshold

Maximum

Outcome

0% vesting

25% vesting

100% vesting

Average annual cumulative EPS Growth over the three financial years 22/23 to 24/25

50%

13.9 %

21.9%

TSR vs FTSE 250 constituents, over 3 years ending 31 July 2025

50%

Below Median

Median

Upper Quartile

 

Performance between the Threshold and Maximum levels will result in a pro-rata increase in the number of Shares vesting, on a straight-line basis. Performance beyond the Maximum level will not result in any additional vesting.

The performance conditions are subject to an underpin, which provides the Remuneration Committee with discretion to adjust or over-ride the formulaic outcome and determine the number of Shares in respect of which the Option will vest, taking into account such factors it may in its discretion determine, potentially including the underlying performance of the Group and the Participant's individual performance.

 

The normal vesting date for each of the Options is 31 August 2025. To the extent that an Option vests, it is subject to a further holding period of two years, during which time it will not be capable of exercise. This means that, in line with the UK Corporate Governance Code, each Option will be subject to an aggregate vesting and holding period of five years and no value can be realized by the option holder until 31 August 2027 at the earliest.

 

The number of Shares shown in the first table above represents the maximum that may be acquired if all performance conditions are achieved in full. The Company may also transfer additional Shares to reflect the value of dividends that would have been paid on the Shares in respect of which the Option vests over the period between the Award Date and the end of the post-vesting holding period.

 

The relevant information set out below is provided in accordance with the requirements of Article 19 of the Market Abuse Regulation as retained in UK law.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Clive Vacher

2

 

Reason for the notification

 

a)

 

Position/status

 

Executive Director/Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

De La Rue plc

b)

 

LEI

 

213800DH741LZWIJXP78

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 44152/175p

 

 

GB00B3DGH821

b)

 

Nature of the transaction

 

 

Grant of a nil-cost option over 454,059 Shares under the rules of the De La Rue Performance Share Plan 2020.

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

 

£0.00

 

454,059

 

 

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

- Aggregated total

N/A

 

 

 

 

 

 

 

e)

 

Date of the transaction

 

31 August 2022

f)

 

Place of the transaction

 

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Rob Harding

2

 

Reason for the notification

 

a)

 

Position/status

 

Executive Director/Chief Financial Officer

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

De La Rue plc

b)

 

LEI

 

213800DH741LZWIJXP78

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 44152/175p

 

 

GB00B3DGH821

b)

 

Nature of the transaction

 

 

Grant of a nil-cost option over 277,480 Shares under the rules of the De La Rue Performance Share Plan 2020.

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

 

£0.00

 

277,480

 

 

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

- Aggregated total

N/A

 

 

 

 

 

 

 

e)

 

Date of the transaction

 

31 August 2022

f)

 

Place of the transaction

 

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Ruth Euling

2

 

Reason for the notification

 

a)

 

Position/status

 

Executive Director/MD, Currency

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

De La Rue plc

b)

 

LEI

 

213800DH741LZWIJXP78

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 44152/175p

 

 

GB00B3DGH821

b)

 

Nature of the transaction

 

 

Grant of a nil-cost option over 252,158 Shares under the rules of the De La Rue Performance Share Plan 2020.

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

 

£0.00

 

252,158

 

 

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

- Aggregated total

N/A

 

 

 

 

 

 

 

e)

 

Date of the transaction

 

31 August 2022

f)

 

Place of the transaction

 

Outside a trading venue

 

Rob Bellhouse, Company Secretary

Contact Number: 01256 605212

1 September 2022

 

De La Rue plc's LEI code is 213800DH741LZWIJXP78.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEAFNFEENAEFA
Date   Source Headline
17th Apr 20247:00 amRNSPre-Close Trading Statement
16th Apr 202411:52 amRNSHolding(s) in Company
16th Apr 202410:59 amRNSHolding(s) in Company
3rd Apr 20247:00 amRNSExtension of contract with Microsoft
2nd Apr 202411:25 amRNSTotal Voting Rights
7th Mar 20241:04 pmRNS2023 AGM Voting Update
23rd Feb 20242:06 pmRNSAdditional Listing
29th Jan 20244:14 pmRNSHolding(s) in Company
26th Jan 20244:38 pmRNSDirector/PDMR Shareholding
18th Jan 20243:19 pmRNSHolding(s) in Company
18th Jan 202412:13 pmRNSHolding(s) in Company
2nd Jan 202411:33 amRNSBlock listing Interim Review
21st Dec 20233:51 pmRNSHolding(s) in Company
19th Dec 20237:00 amRNS2023/24 half year results
27th Nov 20232:53 pmRNSHolding(s) in Company
1st Nov 20231:51 pmRNSTotal Voting Rights
30th Oct 202311:05 amRNSHolding(s) in Company
13th Oct 202310:27 amRNSDirector/PDMR Shareholding
6th Oct 20237:00 amRNSPre-close Trading Statement
2nd Oct 202311:47 amRNSTotal Voting Rights
20th Sep 202312:59 pmRNSDirector/PDMR Shareholding
13th Sep 20231:09 pmRNSHolding(s) in Company
7th Sep 20231:59 pmRNSResult of AGM
7th Sep 20237:00 amRNSAGM statement and trading update
4th Sep 202312:36 pmRNSHolding(s) in Company
1st Sep 20231:15 pmRNSTotal Voting Rights
14th Aug 20233:30 pmRNSHolding(s) in Company
11th Aug 20232:58 pmRNSHolding(s) in Company
11th Aug 20237:00 amRNSDirectorate Change
4th Aug 20237:00 amRNSDirectorate Change
3rd Aug 20239:21 amRNSAppointment of Joint Broker
2nd Aug 20233:26 pmRNSDirector/PDMR Shareholding
1st Aug 20239:00 amRNSTotal Voting Rights
28th Jul 20231:44 pmRNSDirector/PDMR Shareholding
24th Jul 20233:04 pmRNSHolding(s) in Company
20th Jul 20234:03 pmRNSHolding(s) in Company
20th Jul 202312:17 pmRNSAnnual Financial Report
19th Jul 20231:01 pmRNSHolding(s) in Company
11th Jul 202310:28 amRNSDirector/PDMR Shareholding
4th Jul 202312:59 pmRNSHolding(s) in Company
3rd Jul 20235:44 pmRNSHolding(s) in Company
3rd Jul 202312:12 pmRNSBlock listing Interim Review
3rd Jul 202312:09 pmRNSTotal Voting Rights
30th Jun 20231:40 pmRNSHolding(s) in Company
30th Jun 20231:35 pmRNSHolding(s) in Company
30th Jun 202310:11 amRNSDirector/PDMR Shareholding
29th Jun 20237:00 amRNSFY23 full year results
28th Jun 20235:25 pmRNSHolding(s) in Company
28th Jun 20231:50 pmRNSHolding(s) in Company
27th Jun 20231:57 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.